Eudaimonia Partners, LLC Bristol Myers Squibb CO Transaction History

Eudaimonia Partners, LLC

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	BUY	$57.89 - $64.73 $231 - $258	4 Added 0.06%	7,270 $421,000
Q2 2023 Jul 19, 2023	SELL	$63.71 - $70.74 $154,433 - $171,473	-2,424 Reduced 25.02%	7,266 $464,000
Q1 2023 Apr 25, 2023	BUY	$65.71 - $74.53 $13,141 - $14,906	200 Added 2.11%	9,690 $671,000
Q4 2022 Jan 24, 2023	SELL	$68.48 - $81.09 $22,119 - $26,192	-323 Reduced 3.29%	9,490 $0
Q3 2022 Nov 03, 2022	SELL	$0.13 - $76.84 $571 - $337,788	-4,396 Reduced 30.94%	9,813 $698,000
Q2 2022 Aug 09, 2022	SELL	$72.62 - $79.98 $148,653 - $163,719	-2,047 Reduced 12.59%	14,209 $1.09 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $11,004 - $13,195	-179 Reduced 1.09%	16,256 $1.19 Million
Q3 2021 Oct 25, 2021	SELL	$59.17 - $69.31 $115,322 - $135,085	-1,949 Reduced 10.6%	16,435 $972,000
Q2 2021 Aug 13, 2021	BUY	$61.91 - $67.42 $111,561 - $121,490	1,802 Added 10.87%	18,384 $1.23 Million
Q1 2021 May 17, 2021	BUY	$59.34 - $66.74 $28,423 - $31,968	479 Added 2.97%	16,582 $1.05 Million
Q4 2020 Feb 18, 2021	BUY	$57.74 - $65.43 $5,716 - $6,477	99 Added 0.62%	16,103 $998,000
Q3 2020 Nov 23, 2020	BUY	$57.43 - $63.64 $919,109 - $1.02 Million	16,004 New	16,004 $965,000
Q3 2020 Nov 16, 2020	SELL	$57.43 - $63.64 $806,604 - $893,823	-14,045 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$54.82 - $64.09 $18,145 - $21,213	-331 Reduced 2.3%	14,045 $825,000
Q1 2020 May 05, 2020	BUY	$46.4 - $67.43 $9,512 - $13,823	205 Added 1.45%	14,376 $801,000
Q4 2019 May 05, 2020	BUY	$49.21 - $64.19 $697,354 - $909,636	14,171 New	14,171 $909,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Eudaimonia Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Eudaimonia Partners, LLC with notifications on news.